FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Rossing

Research Profile

Disorders

Physiology

Chemicals & Drugs

Concepts & Ideas

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
G Andrésdóttir; S J L Bakker; H P Hansen; Hans-Henrik Parving; Peter Rossing
Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes.
Peter Rossing
Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?
S S Roscioni; Peter Rossing; Petra Zürbig; S J L Bakker; Dick De Zeeuw; Ron T Gansevoort; Merel Elise Hellemons; Maria Lajer; H Mischak; Frederik Persson; H Reinhard; H J Lambers Heerspink
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Rossing (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: G Andrésdóttir; S J L Bakker; H P Hansen; Hans-Henrik Parving; Peter Rossing
Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2013;30(5):563-6.
2013: Peter Rossing
Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?
Nature reviews. Nephrology 2013;9(3):128-30.
2013: S S Roscioni; Peter Rossing; Petra Zürbig; S J L Bakker; Dick De Zeeuw; Ron T Gansevoort; Merel Elise Hellemons; Maria Lajer; H Mischak; Frederik Persson; H Reinhard; H J Lambers Heerspink
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.
Diabetologia 2013;56(2):259-67.
2013: Peter Rossing; Christel Joergensen
Diabetes: Effect of vitamin D on diabetic kidney disease in T1DM.
Nature reviews. Endocrinology 2013;9(1):6-7.
2013: Anne Julie Overgaard; Hans-Henrik Parving; Peter Hovind; James N McGuire; Peter Rossing; Flemming Pociot
Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients.
Journal of diabetes and its complications 2013;27(1):59-63.
2012: Peter Rossing; Susanne Stenkær Ravnkilde; Helle Adolphsen; Charlotte Cerqueira; Søren Friborg
[Quality assurance in the treatment of a public disease: diabetes].
Ugeskrift for laeger 2012;174(42):2551.
2012: Frederik Persson; Peter Rossing
[Renal disease by type 2 diabetes].
Ugeskrift for laeger 2012;174(37):2150-4.
2012: S Theilade; L Tarnow; A Jorsal; Maria Lajer; H-H Parving; Peter Rossing
Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2012;29(8):990-4.
2012: Stine E Nielsen; Hans-Henrik Parving; Henrik Reinhard; Orlando M Gutiérrez; Georg Hess; Peter K Jacobsen; Myles Wolf; Dietmar Walter Zdunek; Peter Rossing
Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients.
Diabetes research and clinical practice 2012;97(1):71-6.
2012: Peter Rossing
Assessment of kidney function: UACR--two risk markers or a 24 h collection in a minute?
Nature reviews. Nephrology 2012;8(6):320-1.
2012: Simone Theilade; Christel Joergensen; Maria Lajer; Frederik Persson; Peter Rossing
Ambulatory tonometric blood pressure measurements in patients with diabetes.
Diabetes technology & therapeutics 2012;14(6):453-6.
2012: Frederik Persson; Camilla Noelle Rathcke; Mari-Anne Gall; Hans-Henrik Parving; Henrik Vestergaard; Peter Rossing
High YKL-40 levels predict mortality in patients with type 2 diabetes.
Diabetes research and clinical practice 2012;96(1):84-9.
2012: S Theilade; L Tarnow; A Jorsal; Maria Lajer; H-H Parving; Peter Rossing
Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 2012;29(3):337-44.
2012: Henrik Reinhard; Peter Rossing; Niels Wiinberg; Kaj Winther; Peter R Hansen; Andreas Kjær; Hans-Henrik Parving; Claus L Petersen; Peter K Jacobsen
NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients.
Cardiovascular diabetology 2012;11():19.
2011: Claudia Cangemi; Jonas Funder; Mari-Anne Gall; Jan Erik Henriksen; Vibeke Hjortdal; Poul Flemming Høilund-Carlsen; Marie Louise Jespersen; Steen Knudsen; Torben A Kruse; Hans-Henrik Parving; Michael Kjaer Poulsen; Jan Aagard; William Scott Argraves; Peter Rossing; Vibe Skov; Waleed O Twal; Lars Melholt Rasmussen
Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes.
Clinical chemistry 2011;57(11):1556-65.
2011: Kenichiro O'goshi; Peter Rossing; Jørgen Serup; Bente Blaaholm; Henrik Klem Thomsen; Lise Tarnow
Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir.
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2011;17(4):411-9.
2011: Lian Engelen; Isabel Ferreira; Peter Hovind; Hans-Henrik Parving; Frederik Persson; Peter Rossing; Coen D Stehouwer; Tom Teerlink; Casper G Schalkwijk
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011;26(11):3573-7.
2011: Henrik Reinhard; Peter Rossing; Lise Tarnow; Niels Wiinberg; Kaj Winther; Andreas Kjær; Hans-Henrik Parving; Frederik Persson; Claus L Petersen; Peter R Hansen; Peter K Jacobsen
Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011;26(10):3242-9.
2011: Merel Elise Hellemons; Stephan J L Bakker; Dick De Zeeuw; Hans-Henrik Parving; Frederik Persson; Peter Rossing; Hiddo J Lambers Heerspink
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.
Diabetes care 2011;34(9):2078-83.
2011: Brad C Astor; Brad C Astor; Priscilla Auguste; Gerald Beck; P J Blankestijn; Barry Brenner; Laura Camarata; Laura E Clark; Josef Coresh; Josef Coresh; Paul E de Jong; Dick de Zeeuw; Ognjenka Djurdjev; Kai-Uwe Eckardt; Meguid El-Nahas; Jonathan Emberson; Nicholas Fluck; Marc Froissart; Ron T Gansevoort; Ron T Gansevoort; Tom Greene; H J Lambers Heerspink; Eric S Johnson; Paul E de Jong; Bertram L Kasiske; Barbara Kollerits; Florian Kronenberg; Martin J Landray; Andrew S Levey; Andrew S Levey; Adeera Levin; Alison Macleod; Angharad Marks; Kunihiro Matsushita; Kunihiro Matsushita; Vandana Menon; Marie Metzger; Hans-Henrik Parving; Annalisa Perna; Gordon Prescott; Giuseppe Remuzzi; Peter Rossing; Piero Ruggenenti; Mark Sarnak; David H Smith; Benedicte Stengel; Beverly Thomas; Micah L Thorp; John N Townend; Marije van der Velde; Marije van der Velde; Arjan Van Zuilen; Kasper Veldhuis; Yaping Wang; Jessica R Weinstein; Jack F Wetzels; David C Wheeler; Mark Woodward; Mark Woodward; Jackson Wright; Tariq Ali; Lawrence J Appel; Tom Manley
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.
Kidney international 2011;79(12):1331-40.
2011: Christel Joergensen; Peter Hovind; Anne Schmedes; Hans-Henrik Parving; Peter Rossing
Vitamin D levels, microvascular complications, and mortality in type 1 diabetes.
Diabetes care 2011;34(5):1081-5.
2011: Kasper Broedbaek; Trine Henriksen; Allan Weimann; Morten Petersen; Jon T Andersen; Shoaib Afzal; Espen Jimenez-Solem; Frederik Persson; Hans-Henrik Parving; Peter Rossing; Henrik E Poulsen
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
Diabetes care 2011;34(5):1192-8.
2011: Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Clinical journal of the American Society of Nephrology : CJASN 2011;6(5):1025-31.
2011: Stine E Nielsen; Steen Andersen; Dietmar Walter Zdunek; Georg Hess; Hans-Henrik Parving; Peter Rossing
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
Kidney international 2011;79(10):1113-8.
2011: Peter Rossing; Dick de Zeeuw
Need for better diabetes treatment for improved renal outcome.
Kidney international. Supplement 2011;(120):S28-32.
2011: Johanna W Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D Stehouwer
Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
Diabetes care 2011;34(2):442-7.
2011: Henrik Reinhard; Peter Rossing; Niels Wiinberg; Kaj Winther; Peter R Hansen; Andreas Kjær; Hans-Henrik Parving; Claus L Petersen; Peter K Jacobsen
NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis.
Cardiovascular diabetology 2011;10():71.
2011: Henrik Reinhard; Peter Rossing; Niels Wiinberg; Kaj Winther; Andreas Kjær; Mads Nybo; Hans-Henrik Parving; Claus L Petersen; Lars M Rasmussen; Peter R Hansen; Peter K Jacobsen
Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria.
Cardiovascular diabetology 2011;10():70.
2011: Amélie Dendooven; Lodewijk Brosens; Dongxia Li; Tri Q Nguyen; Hans-Henrik Parving; Peter Rossing; Lise Tarnow; roel goldschmeding
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes.
Journal of negative results in biomedicine 2011;10():4.
2011: Gert Mayer; Georg Heinze; Harald Mischak; Merel Elise Hellemons; Hiddo J Lambers Heerspink; Stephan J L Bakker; Dick de Zeeuw; Martin Haiduk; Peter Rossing; Rainer Oberbauer
Omics-bioinformatics in the context of clinical data.
Methods in molecular biology (Clifton, N.J.) 2011;719():479-97.
2011: Henrik Reinhard; Lise Tarnow; Anne Sofie Astrup; Nils Billestrup; Peter Karl Jacobsen; Won Yong Kim; Maria Lajer; Thomas Mandrup-Poulsen; Hans-Henrik Parving; Nadja Pedersen; Peter Rossing
Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy.
Nephron. Clinical practice 2011;118(3):c309-14.
2011: Peter Hovind; Peter Rossing; Richard J Johnson; Hans-Henrik Parving
Serum uric acid as a new player in the development of diabetic nephropathy.
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2011;21(1):124-7.
2011: Stine Elkjaer Nielsen; Henrik Post Hansen; Bente Rona Jensen; Hans-Henrik Parving; Peter Rossing
Urinary neutrophil gelatinase-associated lipocalin and progression of diabetic nephropathy in type 1 diabetic patients in a four-year follow-up study.
Nephron. Clinical practice 2011;118(2):c130-5.
2010: Henrik Reinhard; Maria Lajer; Mari-Anne Gall; Lise Tarnow; Hans-Henrik Parving; Lars M Rasmussen; Peter Rossing
Osteoprotegerin and mortality in type 2 diabetic patients.
Diabetes care 2010;33(12):2561-6.
2010: A Alkhalaf; S J L Bakker; H J G Bilo; R O B Gans; gerjan navis; D Postmus; C Forsblom; P H Groop; N Vionnet; S Hadjadj; M Marre; Hans-Henrik Parving; Peter Rossing; L Tarnow
A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus.
Diabetologia 2010;53(12):2562-8.
2010: Christian Delles; Eric Schiffer; Constantin von Zur Muhlen; Karlheinz Peter; Peter Rossing; Hans-Henrik Parving; Jane A Dymott; Ulf Neisius; Lukas U Zimmerli; Janet Snell-Bergeon; David M Maahs; Roland E Schmieder; Harald Mischak; Anna F Dominiczak
Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals.
Journal of hypertension 2010;28(11):2316-22.
2010: Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Diabetes care 2010;33(11):2304-9.
2010: S E Nielsen; K J Schjoedt; A S Astrup; L Tarnow; M Lajer; Peter Riis Hansen; Hans-Henrik Parving; Peter Rossing
Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril.
Diabetic medicine : a journal of the British Diabetic Association 2010;27(10):1144-50.
2010: H Reinhard; P Karl Jacobsen; M Lajer; N Pedersen; N Billestrup; T Mandrup-Poulsen; Hans-Henrik Parving; Peter Rossing
Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes.
Diabetologia 2010;53(10):2129-33.
2010: Christel Joergensen; Mari-Anne Gall; Anne Schmedes; Lise Tarnow; Hans-Henrik Parving; Peter Rossing
Vitamin D levels and mortality in type 2 diabetes.
Diabetes care 2010;33(10):2238-43.
2010: Henning G Hansen; Julie Overgaard; Maria Lajer; Frantisek Hubalek; Peter Højrup; Lykke Pedersen; Lise Tarnow; Peter Rossing; Flemming Pociot; James N McGuire
Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis.
Proteomics. Clinical applications 2010;4(8-9):697-705.
2010: Mischak Harald; Peter Rossing
Proteomic biomarkers in diabetic nephropathy--reality or future promise?
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2010;25(9):2843-5.
2010: Harald Mischak; Günter Allmaier; Rolf Apweiler; Teresa Attwood; Marc Baumann; Ariela Benigni; Samuel E Bennett; Rainer Bischoff; Erik Bongcam-Rudloff; Giovambattista Capasso; Joshua Coon; Patrick D'Haese; Anna F Dominiczak; Mohammed Dakna; Hassan Dihazi; Jochen H Ehrich; Patricia Fernandez-Llama; Danilo Fliser; Jorgen Frokiaer; Jerome Garin; Mark Girolami; William S Hancock; Marion Haubitz; Denis Hochstrasser; Rury R Holman; John Ioannidis; Joachim Jankowski; Bruce A Julian; Jon B Klein; Walter Kolch; Theo Luider; Ziad Massy; William B Mattes; Franck Molina; Bernard Monsarrat; Jan Novak; Karlheinz Peter; Peter Rossing; Marta Sánchez-Carbayo; Joost P Schanstra; O John Semmes; Goce Spasovski; Dan Theodorescu; Visith Thongboonkerd; Raymond Vanholder; Timothy D Veenstra; Eva Weissinger; Tadashi Yamamoto; Antonia Vlahou
Recommendations for biomarker identification and qualification in clinical proteomics.
Science translational medicine 2010;2(46):46ps42.
2010: Johanna W M Nin; Anders Jorsal; Isabel Ferreira; Casper G Schalkwijk; Martin H Prins; Hans-Henrik Parving; Lise Tarnow; Peter Rossing; Coen D A Stehouwer
Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.
Diabetes 2010;59(8):2027-32.
2010: Frederik Persson; Peter Rossing; H Reinhard; T Juhl; C D A Stehouwer; Casper G Schalkwijk; Alexander Hessel Jan Danser; F Boomsma; E Frandsen; Hans-Henrik Parving
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.
Diabetologia 2010;53(8):1576-80.
2010: Maria Lajer; Anders Jorsal; Lise Tarnow; Hans-Henrik Parving; Peter Rossing
Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
Diabetes care 2010;33(7):1567-72.
2010: Stine Elkjaer Nielsen; Takeshi Sugaya; Peter Hovind; Tsuneharu Baba; Hans-Henrik Parving; Peter Rossing
Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.
Diabetes care 2010;33(6):1320-4.
2010: Anna F Dominiczak; Stefan Herget-Rosenthal; Christian Delles; Danilo Fliser; Isabelle Fournier; Armin Graber; Mark Girolami; Elaine Holmes; Florian Lang; Franck Molina; Jeremy Nicholson; Giuseppe Remuzzi; Peter Rossing; Karl Lenhard Rudolph; Olaf Wolkenhauer; Ioannis Xenarios; Roman Zubarev; Dimitry Zubov; Antonia Vlahou; Joost P Schanstra
Systems biology to battle vascular disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2010;25(4):1019-22.
2010: Lesley A Stevens; Christopher Schmid; Yaping L Zhang; Josef Coresh; Jane Manzi; Richard Landis; Omran Bakoush; Gabriel Contreras; Saul Genuth; Goran B Klintmalm; Emilio Poggio; Peter Rossing; Andrew D Rule; Matthew R Weir; John W Kusek; Tom Greene; Andrew S Levey
Development and validation of GFR-estimating equations using diabetes, transplant and weight.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2010;25(2):449-57.
2010: Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
BMC nephrology 2010;11():29.
2010: Alaa Alkhalaf; Petra Zürbig; Stephan J L Bakker; Henk J G Bilo; Marie Cerna; Christine Fischer; Sebastian Fuchs; Bart Janssen; Karel Medek; Harald Mischak; Johannes M Roob; Kasper Rossing; Peter Rossing; Ivan Rychlík; Harald Sourij; Beate Tiran; Brigitte M Winklhofer-Roob; Gerjan J Navis
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy.
PloS one 2010;5(10):e13421.
2010: David M Maahs; Justyna Siwy; Angel Argilés; Marie Cerna; Christian Delles; Anna F Dominiczak; Nathalie Gayrard; Alexander Iphöfer; Lothar Jänsch; George Jerums; Karel Medek; Mischak Harald; Gerjan J Navis; Johannes M Roob; Kasper Rossing; Peter Rossing; Ivan Rychlík; Eric Schiffer; Roland E Schmieder; Thomas C Wascher; Brigitte M Winklhofer-Roob; Lukas U Zimmerli; Petra Zürbig; Janet Snell-Bergeon
Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.
PloS one 2010;5(9):.
2010: Maria Lajer; Inge Tarnow; Alan D Michelson; Anders Jorsal; Andrew L Frelinger; Hans-Henrik Parving; Peter Rossing; Lise Tarnow
Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
Platelets 2010;21(7):525-32.
2010: Anne Julie Overgaard; Henning Gram Hansen; Maria Lajer; Lykke Pedersen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy.
Proteome science 2010;8():4.
2010: A S Astrup; L Tarnow; A Jorsal; M Lajer; R Nzietchueng; A Benetos; Peter Rossing; H-H Parving
Telomere length predicts all-cause mortality in patients with type 1 diabetes.
Diabetologia 2010;53(1):45-8.
2009: Inge Tarnow; Alan D Michelson; Marc R Barnard; Andrew L Frelinger; Bent Aasted; Berit R Jensen; Hans-Henrik Parving; Peter Rossing; Lise Tarnow
Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity.
Platelets 2009;20(7):513-9.
2009: Katrine J Schjoedt; Per K Christensen; Anders Jorsal; Frans Boomsma; Peter Rossing; Hans-Henrik Parving
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2009;24(11):3343-9.
2009: Frederik Persson; Peter Rossing; Henrik Reinhard; Tina Juhl; Coen D A Stehouwer; Casper G Schalkwijk; Alexander Hessel Jan Danser; Frans Boomsma; Erik Frandsen; Hans-Henrik Parving
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
Diabetes care 2009;32(10):1873-9.
2009: Søren S Lund; Lise Tarnow; Anne Sofie Astrup; Peter Hovind; P K Jacobsen; A C Alibegovic; I Parving; L Pietraszek; M Frandsen; Peter Rossing; Hans-Henrik Parving; Allan Vaag
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.
Diabetes, obesity & metabolism 2009;11(10):966-77.
2009: Stine E Nielsen; takeshi sugaya; Lise Tarnow; Maria Lajer; Katrine J Schjoedt; Anne Sofie Astrup; Tsuneharu Baba; Hans-Henrik Parving; Peter Rossing
Tubular and glomerular injury in diabetes and the impact of ACE inhibition.
Diabetes care 2009;32(9):1684-8.
2009: Peter Hovind; Peter Rossing; Lise Tarnow; Richard J Johnson; Hans-Henrik Parving
Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study.
Diabetes 2009;58(7):1668-71.
2009: Per Løgstrup Poulsen; Klavs Würgler Hansen; Peter Haulund Gaede; Peter Rossing
[Hypertension in patients with diabetes].
Ugeskrift for laeger 2009;171(24):2031-4.
2009: Lars Juhl Petersen; Henrik Birn; Søren A Ladefoged; Else Randers; Michael Rehling; Birgitte Reinholdt; Peter Rossing
[Clinical assessment of excretory renal function].
Ugeskrift for laeger 2009;171(13):1090.
2009: Camilla Noelle Rathcke; Frederik Persson; Lise Tarnow; Peter Rossing; Henrik Vestergaard
YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria.
Diabetes care 2009;32(2):323-8.
2009: Søren S Lund; Peter Rossing; Allan A Vaag
Follow-up of intensive glucose control in type 2 diabetes.
The New England journal of medicine 2009;360(4):416; author reply 418.
2009: K J Schjoedt; A S Astrup; Frederik Persson; E Frandsen; F Boomsma; K Rossing; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
Diabetologia 2009;52(1):46-9.
2008: Peter Rossing
Is renal Na+,K+-ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?
The Journal of physiology 2008;586(Pt 22):5283.
2008: A Jorsal; Lise Tarnow; Allan Flyvbjerg; Hans-Henrik Parving; Peter Rossing; L M Rasmussen
Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy.
Diabetologia 2008;51(11):2100-7.
2008: Anders Jorsal; Lise Tarnow; Jan Frystyk; Maria Lajer; Allan Flyvbjerg; Hans-Henrik Parving; Nathalie Vionnet; Peter Rossing
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy.
Kidney international 2008;74(5):649-54.
2008: Henrik Leth; Kristian K Andersen; Jan Frystyk; Lise Tarnow; Peter Rossing; Hans-Henrik Parving; Allan Flyvbjerg
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.
The Journal of clinical endocrinology and metabolism 2008;93(8):3186-91.
2008: Kasper Rossing; Mischak Harald; Peter Rossing; Joost P Schanstra; Alex Wiseman; David M Maahs
The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy.
Proteomics. Clinical applications 2008;2(7-8):997-1007.
2008: Kasper Rossing; Mischak Harald; Mohammed Dakna; Petra Zürbig; Jan Novak; Bruce A Julian; David M Good; Joshua Coon; Lise Tarnow; Peter Rossing
Urinary proteomics in diabetes and CKD.
Journal of the American Society of Nephrology : JASN 2008;19(7):1283-90.
2008: K J Schjoedt; H P Hansen; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Long-term prevention of diabetic nephropathy: an audit.
Diabetologia 2008;51(6):956-61.
2008: Tri Q Nguyen; Lise Tarnow; Anders Jorsal; Noelynn Oliver; Peggy Roestenberg; Yasuhiko Ito; Hans-Henrik Parving; Peter Rossing; Frans A van Nieuwenhoven; roel goldschmeding
Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy.
Diabetes care 2008;31(6):1177-82.
2008: Frederik Persson; Peter Rossing; K J Schjoedt; T Juhl; L Tarnow; C D A Stehouwer; C Schalkwijk; F Boomsma; E Frandsen; H-H Parving
Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes.
Kidney international 2008;73(12):1419-25.
2008: Anne Sofie Astrup; Lise Tarnow; Lotte Pietraszek; Casper G Schalkwijk; Coen D A Stehouwer; Hans-Henrik Parving; Peter Rossing
Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate.
Diabetes care 2008;31(6):1170-6.
2008: Hans-Henrik Parving; Dick de Zeeuw; Mark E Cooper; Giuseppe Remuzzi; Nancy Liu; Jared Lunceford; Shahnaz Shahinfar; Peggy H Wong; Paulette A Lyle; Peter Rossing; Barry M Brenner
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
Journal of the American Society of Nephrology : JASN 2008;19(4):771-9.
2008: Maria Lajer; Lise Tarnow; Anders Jorsal; Tom Teerlink; Hans-Henrik Parving; Peter Rossing
Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2008;31(4):747-52.
2008: Søren S Lund; Lise Tarnow; Anne Sofie Astrup; Peter Hovind; Peter Karl Jacobsen; Amra Ciric Alibegovic; Ida Parving; Lotte Pietraszek; Merete Frandsen; Peter Rossing; Hans-Henrik Parving; Allan Vaag
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
PloS one 2008;3(10):e3363.
2008: Frederik Persson; Peter Rossing; Peter Hovind; Coen D A Stehouwer; Casper G Schalkwijk; Lise Tarnow; Hans-Henrik Parving
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Scandinavian journal of clinical and laboratory investigation 2008;68(8):731-8.
2007: Anne Sofie Astrup; Flemming S Nielsen; Peter Rossing; Samir Ali; Jens Kastrup; Ulla Meng Smidt; Hans-Henrik Parving
Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study.
Journal of hypertension 2007;25(12):2479-85.
2007: Anne Sofie Astrup; Lise Tarnow; M Christiansen; P R Hansen; Hans-Henrik Parving; Peter Rossing
Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(12):1381-5.
2006: Frederik Persson; Peter Rossing; Peter Hovind; Coen D A Stehouwer; Casper Schalkwijk; Lise Tarnow; Hans-Henrik Parving
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Diabetes 2006;55(12):3550-5.
2006: Peter Rossing
Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history.
Current diabetes reports 2006;6(6):479-83.
2006: Peter Rossing; Hans-Henrik Parving; Dick de Zeeuw
Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(9):2354-7; discussion 2357-8.
2006: Katrine J Schjoedt; Kasper Rossing; Tina R Juhl; Frans Boomsma; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
Kidney international 2006;70(3):536-42.
2006: Peter Karl Jacobsen; Peter Rossing; Hans-Henrik Parving
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21(7):2030-1.
2006: Peter Rossing; Kasper Rossing; Peter Gaede; Oluf Pedersen; Hans-Henrik Parving
Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy.
Diabetes care 2006;29(5):1024-30.
2006: Peter Rossing; Hans-Henrik Parving
[ACE inhibitors and AT-II antagonists--do they protect against renal disease?].
Ugeskrift for laeger 2006;168(15):1564; author reply1564-5.
2006: Hans-Henrik Parving; Peter Rossing
Renoprotective effects of renin-angiotensin-system inhibitors.
Lancet 2006;367(9514):898-9; author reply 900-2.
2006: Peter Rossing; Mark E Cooper; Hans-Henrik Parving
Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes.
Diabetes care 2006;29(3):747-8; author reply 748-9.
2006: Anne Sofie Astrup; Lise Tarnow; Peter Rossing; Birgitte V Hansen; Jannik Hilsted; Hans-Henrik Parving
Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2006;29(2):334-9.
2006: Katrine J Schjoedt; Maria Lajer; Steen Andersen; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 2006;66(3):173-80.
2006: Peter Rossing
Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.
Diabetologia 2006;49(1):11-9.
2005: Katrine J Schjoedt; Kasper Rossing; Tina R Juhl; Frans Boomsma; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Beneficial impact of spironolactone in diabetic nephropathy.
Kidney international 2005;68(6):2829-36.
2005: Peter Rossing; Philip Hougaard; Hans-Henrik Parving
Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study.
Kidney international 2005;68(4):1446-50.
2005: Anne Sofie Astrup; Lise Tarnow; Peter Rossing; Lotte Pietraszek; Peter Riis Hansen; Hans-Henrik Parving
Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study.
Kidney international 2005;68(3):1250-7.
2005: Sofia B Ahmed; Peter Hovind; Hans-Henrik Parving; Peter Rossing; Deborah A Price; Lori M B Laffel; M Cecilia Lansang; Radomir Stevanovic; Naomi D L Fisher; Norman K Hollenberg
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
Diabetes care 2005;28(8):1988-94.
2005: Peter Rossing
The changing epidemiology of diabetic microangiopathy in type 1 diabetes.
Diabetologia 2005;48(8):1439-44.
2005: Steen Andersen; Frans A van Nieuwenhoven; Lise Tarnow; Peter Rossing; Kasper Rossing; Lotte Wieten; roel goldschmeding; Hans-Henrik Parving
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Kidney international 2005;67(6):2325-9.
2005: Gozewijn D Laverman; Steen Andersen; Peter Rossing; gerjan navis; Dick De Zeeuw; Hans-Henrik Parving
Renoprotection with and without blood pressure reduction.
Kidney international. Supplement 2005;(94):S54-9.
2005: Hans-Henrik Parving; Peter Hovind; Peter Rossing
Telmisartan vs. enalapril in type 2 diabetes.
The New England journal of medicine 2005;352(8):835-6; author reply 835-6.
2005: Peter Hovind; Lise Tarnow; Peter Rossing; Bente Rona Jensen; Malene Graae; Inge Torp; Christian Binder; Hans-Henrik Parving
[Risk factors for the development of microalbuminuria in type 1 diabetes: an incidence cohort study--a secondary publication].
Ugeskrift for laeger 2005;167(1):57-60.
2004: Katrine J Schjoedt; Steen Andersen; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Diabetologia 2004;47(11):1936-9.
2004: Kasper Rossing; Per K Christensen; Peter Hovind; Lise Tarnow; Peter Rossing; Hans-Henrik Parving
Progression of nephropathy in type 2 diabetic patients.
Kidney international 2004;66(4):1596-605.
2004: Peter Hovind; Lise Tarnow; Peter Rossing; Bendix Carstensen; Hans-Henrik Parving
Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.
Kidney international 2004;66(3):1180-6.
2004: Peter Hovind; Lise Tarnow; Peter Rossing; Bente Rona Jensen; Malene Graae; Inge Torp; Christian Binder; Hans-Henrik Parving
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study.
BMJ (Clinical research ed.) 2004;328(7448):1105.
2004: Hans-Henrik Parving; Steen Andersen; Peter Jacobsen; Per K Christensen; Kasper Rossing; Peter Hovind; Peter Rossing; Lise Tarnow
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Seminars in nephrology 2004;24(2):147-57.
2003: Steen Andersen; Lise Tarnow; François Cambien; Peter Rossing; Tina R Juhl; jaap deinum; Hans-Henrik Parving
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Diabetes care 2003;26(5):1501-6.
2003: Peter Hovind; Lise Tarnow; Kasper Rossing; Peter Rossing; Stefanie Eising; Nicolai Larsen; Christian Binder; Hans-Henrik Parving
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.
Diabetes care 2003;26(4):1258-64.
2003: Peter Hovind; Peter Rossing; Lise Tarnow; Hans-Henrik Parving
Smoking and progression of diabetic nephropathy in type 1 diabetes.
Diabetes care 2003;26(3):911-6.
2003: Peter Jacobsen; Peter Rossing; Lise Tarnow; Peter Hovind; Hans-Henrik Parving
Birth weight--a risk factor for progression in diabetic nephropathy?
Journal of internal medicine 2003;253(3):343-50.
2003: Steen Andersen; Peter Jacobsen; Lise Tarnow; Peter Rossing; Tina R Juhl; Hans-Henrik Parving
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003;18(2):293-7.
2002: Steen Andersen; Peter Rossing; Tina R Juhl; jaap deinum; Hans-Henrik Parving
Optimal dose of losartan for renoprotection in diabetic nephropathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2002;17(8):1413-8.
2002: Steen Andersen; Lise Tarnow; François Cambien; Peter Rossing; Tina R Juhl; jaap deinum; Hans-Henrik Parving
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Kidney international 2002;62(1):192-8.
2002: Peter Rossing; Philip Hougaard; Hans-Henrik Parving
Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study.
Diabetes care 2002;25(5):859-64.
2002: Kasper Rossing; P Jacobsen; EE Hommel; Elisabeth R Mathiesen; A Svenningsen; Peter Rossing; Hans-Henrik Parving
Pregnancy and progression of diabetic nephropathy.
Diabetologia 2002;45(1):36-41.
2001: Peter Hovind; Lise Tarnow; Peter Rossing; T Teerlink; C D Stehouwer; J J Emeis; Hans-Henrik Parving
Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;38(6):1376-80.
2001: Peter Hovind; Peter Rossing; Lise Tarnow; H Toft; J Parving; Hans-Henrik Parving
Remission of nephrotic-range albuminuria in type 1 diabetic patients.
Diabetes care 2001;24(11):1972-7.
2001: Peter Hovind; Peter Rossing; Lise Tarnow; Ulla M Smidt; Hans-Henrik Parving
Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively.
Kidney international 2001;60(1):277-83.
2001: Peter Rossing; L Breum; A Major-Pedersen; A Sato; H Winding; A Pietersen; J Kastrup; Hans-Henrik Parving
Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association 2001;18(3):199-205.
2001: Peter Hovind; Peter Rossing; Lise Tarnow; Ulla M Smidt; Hans-Henrik Parving
Progression of diabetic nephropathy.
Kidney international 2001;59(2):702-9.
2001: Henrik Post Hansen; Søren S Lund; Peter Rossing; Lise Tarnow; Flemming S Nielsen; T Jensen; Hans-Henrik Parving
Preventing diabetic nephropathy: an audit.
Scandinavian journal of clinical and laboratory investigation 2001;61(6):471-7.
2001: B Myrup; Peter Rossing; T Jensen; Hans-Henrik Parving; G Hølmer; J Gram; Cornelis Kluft; J Jespersen
Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 2001;61(5):349-56.
2001: H H Parving; Peter Rossing
Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.
Diabetes care 2001;24(1):177-80.
2000: Lise Tarnow; Peter Rossing; C Jensen; Birgitte V Hansen; Hans-Henrik Parving
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2000;23(12):1725-30.
2000: Peter Rossing
[Risk factors in the progression of diabetic nephropathies].
Ugeskrift for laeger 2000;162(38):5057-61.
2000: Per K Christensen; Mari-Anne Gall; A Major-Pedersen; A Sato; Peter Rossing; L Breum; A Pietersen; J Kastrup; Hans-Henrik Parving
QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes.
Scandinavian journal of clinical and laboratory investigation 2000;60(4):323-32.
2000: H Bos; S Andersen; Peter Rossing; D De Zeeuw; H H Parving; P E De Jong; gerjan navis
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.
Kidney international. Supplement 2000;75():S32-7.
2000: Steen Andersen; Lise Tarnow; Peter Rossing; Birgitte V Hansen; Hans-Henrik Parving
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Kidney international 2000;57(2):601-6.
2000: Lise Tarnow; Peter Rossing; Flemming S Nielsen; Johan Fagerudd; O Poirier; Hans-Henrik Parving
Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy.
Diabetes care 2000;23(1):30-3.
1999: Flemming S Nielsen; Henrik Post Hansen; Peter Jacobsen; Peter Rossing; Ulla M Smidt; N J Christensen; Pevet P; Berthe Vivien-Roels; Hans-Henrik Parving
Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(7):555-62.
1999: Peter Jacobsen; Kasper Rossing; Lise Tarnow; Peter Rossing; C Mallet; O Poirier; François Cambien; Hans-Henrik Parving
Progression of diabetic nephropathy in normotensive type 1 diabetic patients.
Kidney international. Supplement 1999;71():S101-5.
1999: Per K Christensen; Peter Rossing; Flemming S Nielsen; Hans-Henrik Parving
Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(5):388-94.
1999: Lise Tarnow; A Sato; S Ali; Peter Rossing; Flemming S Nielsen; Hans-Henrik Parving
Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.
Diabetes care 1999;22(3):491-4.
1999: Hans-Henrik Parving; Lise Tarnow; Flemming S Nielsen; Peter Rossing; Thomas Mandrup-Poulsen; R Osterby; Jørn Nerup
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.
Diabetes care 1999;22(3):478-83.
1998: V B Sørensen; Peter Rossing; L Tarnow; H Parving; Tove Nørgaard; Jens Kastrup
Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy.
Clinical science (London, England : 1979) 1998;95(6):709-17.
1998: Peter Rossing
Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association 1998;15(11):900-19.
1998: Kasper Rossing; Peter Jacobsen; Peter Rossing; E Lauritzen; H Lund-Andersen; Hans-Henrik Parving
Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy.
Diabetes care 1998;21(11):2007-15.
1998: H H Parving; Peter Rossing
Diabetes and risk of adverse events with calcium antagonists.
Diabetes care 1998;21(10):1779-80.
1998: Peter Rossing
Promotion, prediction, and prevention of progression in diabetic nephropathy.
Danish medical bulletin 1998;45(4):354-69.
1998: L Tarnow; HH Parving; P Jacobsen; Peter Rossing; L Lecerf; O Poirier; F Cambien
[The significance of deletion polymorphism in the ACE gene for progression of diabetic nephropathies treated with ACE inhibitors].
Ugeskrift for laeger 1998;160(34):4886-9.
1998: Henrik Post Hansen; Peter Rossing; Elisabeth R Mathiesen; EE Hommel; Ulla M Smidt; Hans-Henrik Parving
Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of 51Cr-EDTA.
Scandinavian journal of clinical and laboratory investigation 1998;58(5):405-13.
1998: Peter Jacobsen; Kasper Rossing; Peter Rossing; Lise Tarnow; C Mallet; O Poirier; François Cambien; Hans-Henrik Parving
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy.
Kidney international 1998;53(4):1002-6.
1998: Peter Rossing; Philip Hougaard; K Borch-Johnsen; Hans-Henrik Parving
[Risk factors for mortality in patients with insulin-dependent diabetes].
Ugeskrift for laeger 1998;160(9):1315-9.
1998: Peter Rossing
Doubling of serum creatinine: is it sensitive and relevant?
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1998;13(2):244-6.
1997: Henrik Post Hansen; Flemming S Nielsen; Peter Rossing; Peter Jacobsen; Bente Rona Jensen; Hans-Henrik Parving
Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.
Kidney international. Supplement 1997;63():S49-53.
1997: Flemming S Nielsen; Peter Rossing; Mari-Anne Gall; Ulla M Smidt; J W Chen; A Sato; Hans-Henrik Parving
Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 1997;57(5):427-34.
1997: Flemming S Nielsen; S Ali; Peter Rossing; Lia E Bang; Tage Lysbo Svendsen; Mari-Anne Gall; Ulla M Smidt; J Kastrup; Hans-Henrik Parving
Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy.
Diabetic medicine : a journal of the British Diabetic Association 1997;14(7):538-46.
1997: Flemming S Nielsen; Peter Rossing; Mari-Anne Gall; P Skøtt; Ulla M Smidt; Hans-Henrik Parving
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Diabetes 1997;46(7):1182-8.
1997: Lise Tarnow; Flemming Pociot; PM Hansen; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; Hans-Henrik Parving
Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM.
Diabetes 1997;46(6):1075-6.
1997: Peter Rossing; Lise Tarnow; S Boelskifte; Bente Rona Jensen; Flemming S Nielsen; Hans-Henrik Parving
Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Diabetes 1997;46(3):481-7.
1997: Hans-Henrik Parving; Lise Tarnow; Peter Rossing
Renal protection in diabetes--an emerging role for calcium antagonists.
Cardiology 1997;88 Suppl 3():56-62.
1996: Peter Rossing; Lise Tarnow; Flemming S Nielsen; Birgitte V Hansen; B M Brenner; H H Parving
[Low birth weight--increased risk of diabetic nephropathies?].
Ugeskrift for laeger 1996;159(1):41-4.
1996: H H Parving; Lise Tarnow; Peter Rossing
Genetics of diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 1996;7(12):2509-17.
1996: H H Parving; Flemming S Nielsen; Lia E Bang; Ulla M Smidt; T L Svendsen; J W Chen; Mari-Anne Gall; Peter Rossing
Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy.
Diabetologia 1996;39(12):1590-7.
1996: Lise Tarnow; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; J Dyerberg; H H Parving
Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy.
Diabetes care 1996;19(12):1382-7.
1996: H H Parving; Lise Tarnow; Peter Rossing
Renal protection in diabetes: an emerging role for calcium antagonists.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1996;14(4):S21-5.
1996: Peter Rossing; Birgitte V Hansen; Flemming S Nielsen; B Myrup; G Hølmer; H H Parving
Fish oil in diabetic nephropathy.
Diabetes care 1996;19(11):1214-9.
1996: Peter Rossing; Kasper Rossing; P Jacobsen; H H Parving
[Diabetic nephropathy. Unchanged occurrence in patients with insulin-dependent diabetes mellitus].
Ugeskrift for laeger 1996;158(42):5940-3.
1996: Peter Rossing; Philip Hougaard; K Borch-Johnsen; H H Parving
Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.
BMJ (Clinical research ed.) 1996;313(7060):779-84.
1996: H H Parving; P Jacobsen; Lise Tarnow; Peter Rossing; L Lecerf; O Poirier; F Cambien
Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
BMJ (Clinical research ed.) 1996;313(7057):591-4.
1996: Henrik Post Hansen; Peter Rossing; Lise Tarnow; Flemming S Nielsen; Bente Rona Jensen; H H Parving
Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy.
Kidney international 1996;50(2):579-85.
1996: H H Parving; Peter Jacobsen; Kasper Rossing; Ulla M Smidt; EE Hommel; Peter Rossing
Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy.
Kidney international 1996;49(6):1778-82.
1996: Lise Tarnow; François Cambien; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; Sylvain Ricard; O Poirer; H H Parving
Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1996;11(6):1019-23.
1996: H Yokoyama; B Myrup; Peter Rossing; P B Ostergaard
Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.
Diabetes care 1996;19(5):441-5.
1996: Lise Tarnow; François Cambien; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; Sylvain Ricard; Odette Poirier; H H Parving
Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy.
Diabetes 1996;45(3):367-369.
1996: B Myrup; M de Maat; Peter Rossing; J Gram; Cornelis Kluft; J Jespersen
Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy.
Thrombosis research 1996;81(4):485-90.
1995: Peter Rossing; Lise Tarnow; Flemming S Nielsen; Birgitte V Hansen; B M Brenner; H H Parving
Low birth weight. A risk factor for development of diabetic nephropathy?
Diabetes 1995;44(12):1405-7.
1995: Flemming S Nielsen; Peter Rossing; Lia E Bang; T L Svendsen; Mari-Anne Gall; Ulla M Smidt; H H Parving
On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy.
Diabetes 1995;44(7):783-9.
1995: Peter Rossing; Kasper Rossing; Peter Jacobsen; H H Parving
Unchanged incidence of diabetic nephropathy in IDDM patients.
Diabetes 1995;44(7):739-43.
1995: H H Parving; Peter Rossing; EE Hommel; Ulla M Smidt
Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1995;26(1):99-107.
1995: Lise Tarnow; François Cambien; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; L Lecerf; Odette Poirier; S Danilov; S Boelskifte; K Borch-Johnsen
Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.
Diabetologia 1995;38(7):798-803.
1995: Henrik Post Hansen; Peter Rossing; Lise Tarnow; Flemming S Nielsen; Bente Rona Jensen; H H Parving
Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.
Kidney international 1995;47(6):1726-31.
1995: Lise Tarnow; François Cambien; Peter Rossing; Flemming S Nielsen; Birgitte V Hansen; L Lecerf; Odette Poirier; S Danilov; H H Parving
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients.
Diabetes 1995;44(5):489-94.
1995: Peter Rossing; Lise Tarnow; Flemming S Nielsen; S Boelskifte; B M Brenner; H H Parving
Short stature and diabetic nephropathy.
BMJ (Clinical research ed.) 1995;310(6975):296-7.
1995: B Myrup; Peter Rossing; T Jensen; J Gram; Cornelis Kluft; J Jespersen
Procoagulant activity and intimal dysfunction in IDDM.
Diabetologia 1995;38(1):73-8.
1994: Lise Tarnow; Peter Rossing; Mari-Anne Gall; Flemming S Nielsen; H H Parving
Prevalence of arterial hypertension in diabetic patients before and after the JNC-V.
Diabetes care 1994;17(11):1247-51.
1994: Flemming S Nielsen; Peter Rossing; Mari-Anne Gall; Peter Skøtt; Ulla M Smidt; H H Parving
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Diabetes 1994;43(9):1108-13.
1994: Peter Rossing; A S Astrup; Ulla M Smidt; H H Parving
Monitoring kidney function in diabetic nephropathy.
Diabetologia 1994;37(7):708-12.
1994: Peter Rossing; EE Hommel; Ulla M Smidt; H H Parving
Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.
Diabetologia 1994;37(5):511-6.
1994: H H Parving; Peter Rossing
The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
Current opinion in nephrology and hypertension 1994;3(3):292-300.
1994: Mari-Anne Gall; Peter Rossing; A Kofoed-Enevoldsen; Flemming S Nielsen; H H Parving
Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.
Diabetologia 1994;37(2):195-201.
1994: Peter Rossing; EE Hommel; Ulla M Smidt; H H Parving
Reduction in albuminuria predicts diminished progression in diabetic nephropathy.
Kidney international. Supplement 1994;45():S145-9.
1993: H H Parving; Ulla M Smidt; EE Hommel; Elisabeth R Mathiesen; Peter Rossing; F Nielsen; Mari-Anne Gall
Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;22(1):188-95.
1993: H H Parving; Peter Rossing
Calcium antagonists and the diabetic hypertensive patient.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;21(6 Suppl 3):47-52.
1993: Peter Rossing; EE Hommel; Ulla M Smidt; H H Parving
Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients.
Diabetes 1993;42(5):715-9.
1993: Flemming S Nielsen; A I Voldsgaard; Mari-Anne Gall; Peter Rossing; EE Hommel; P Andersen; J Dyerberg; H H Parving
Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.
Diabetologia 1993;36(5):438-44.
1993: Mari-Anne Gall; Peter Rossing; Peter Skøtt; EE Hommel; Elisabeth R Mathiesen; Ulrik Gerdes; M Lauritzen; A Vølund; O Faergeman; H Beck-Nielsen
[The effect of captopril, metoprolol and hydrochlorothiazide therapy in patients with non-insulin-dependent diabetes (NIDDM) and primary hypertension. A double-blind, randomized cross-over study].
Ugeskrift for laeger 1993;155(9):636-41.
1992: Mari-Anne Gall; Peter Rossing; EE Hommel; A I Voldsgaard; P Andersen; Flemming S Nielsen; J Dyerberg; H H Parving
Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy.
Scandinavian journal of clinical and laboratory investigation 1992;52(6):513-21.
1992: Mari-Anne Gall; Peter Rossing; Peter Skøtt; EE Hommel; Elisabeth R Mathiesen; Ulrik Gerdes; M Lauritzen; A Vølund; O Faergeman; H Beck-Nielsen
Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension.
American journal of hypertension 1992;5(5 Pt 1):257-65.
1992: EE Hommel; P Andersen; Mari-Anne Gall; F Nielsen; B Jensen; Peter Rossing; J Dyerberg; H H Parving
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.
Diabetologia 1992;35(5):447-51.
1991: Mari-Anne Gall; Peter Rossing; Peter Skøtt; P Damsbo; Allan Vaag; K Bech; A Dejgaard; M Lauritzen; E Lauritzen; Philip Hougaard
Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients.
Diabetologia 1991;34(9):655-61.
1991: Mari-Anne Gall; Peter Rossing; J S Jensen; J Funder; H H Parving
Red cell Na+/Li+ countertransport in non-insulin-dependent diabetics with diabetic nephropathy.
Kidney international 1991;39(1):135-40.